| Literature DB >> 23212274 |
Tomasz Miszalski-Jamka1, Wojciech Szczeklik, Barbara Sokołowska, Krzysztof Karwat, Katarzyna Belzak, Wojciech Mazur, Dean J Kereiakes, Jacek Musiał.
Abstract
The aim of the study was to evaluate the presence and spectrum of cardiac abnormalities identified by cardiac magnetic resonance (CMR) in subjects in clinical remission of Churg-Strauss syndrome (CSS) and granulomatosis with polyangiitis (Wegener's) (WG) with normal ECG and transthoracic echocardiography (TTE). Eleven (7 females, 4 males, mean age 42.4 ± 9.6 years) CSS and 10 (4 females, 6 males, mean age 45.3 ± 10.9 years) WG patients in clinical remission with normal ECG and TTE underwent CMR. Segmental peak-systolic myocardial strain (εps) was measured using feature tracking cine-sequence based technique. Left ventricular (LV) ejection fraction, end-diastolic volume and myocardial mass indexes were 66.2 ± 5.8 %, 66.1 ± 6.6 ml/m(2), and 61.0 ± 8.9 g/m(2), respectively. No patient showed regional wall motion abnormalities and signs of myocarditis. Nine CSS and 8 WG patients demonstrated decreased segmental longitudinal, circumferential or radial εps and myocardial late gadolinium enhancement (LGE) (6 subendocardial, 10 midwall, 8 subepicardial) areas. In CSS and WG subjects with LVLGE lesions the mean LVLGE extent was 2.0 ± 1.6 % and 2.3 ± 1.5 % (p = 0.65), respectively. Segmental εps was decreased longitudinally (-11.8 ± 5.6 %) for subendocardial LGE, radially (13.7 ± 8.7 %) for subepicardial LGE, and circumferentially (-16.6 ± 4.2 %), longitudinally (-13.2 ± 5.5 %) and radially (18.8 ± 8.1 %) for midwall LGE, if compared to longitudinal (-22.7 ± 5.1 %), circumferential (-23.6 ± 5.6 %) and radial (34.2 ± 15.7 %) εps in controls (11 females, 10 males, mean age 43.9 ± 10.5 years) (all p < 0.01). Despite clinical remission, normal ECG and TTE, most CSS and WG patients demonstrate decreased segmental εps and non-ischemic LGE lesions without signs of myocarditis.Entities:
Mesh:
Year: 2012 PMID: 23212274 PMCID: PMC3644401 DOI: 10.1007/s10554-012-0158-6
Source DB: PubMed Journal: Int J Cardiovasc Imaging ISSN: 1569-5794 Impact factor: 2.357
Patient characteristics
| CCS (n = 11) / WG (n = 10) |
| |
|---|---|---|
| Female/male | 7/4 / 4/6 | 0.39 |
| Age [years] | 42.4 ± 9.6 / 45.3 ± 10.9 | 0.30 |
| Time since diagnosis [years] | 4.7 ± 2.8 / 4.8 ± 3.9 | 0.99 |
|
| ||
| Positive cANCA/pANCA | 0/3 / 10/2 | 0.02 |
| ANCA titrea | 20 (20–30) / 20 (12.5–70) | 0.81 |
| PR3-ANCA titrea | 0 (0–0) / 20 (20–40) | <0.001 |
| White blood cells [103cells/μl] | 7.5 ± 3.7 / 7.5 ± 2.9 | 0.99 |
| Blood eosinophilia [cells/μl] | 198 ± 128 / 121 ± 53 | 0.09 |
| CRP [mg/l] | 3.2 ± 2.9 / 5.8 ± 5.3 | 0.12 |
| Creatinine clearance [ml/min] | 92 ± 18 / 101 ± 41 | 0.52 |
| Positive troponin I | 0 / 0 | >0.99 |
| Treatment: C/M/Az/Cy | 1/0/2/2 / 3/1/0/0 | 0.20 |
| Treatment: G | 11/10 | >0.99 |
|
| ||
| Ever positive cANCA/pANCA | 0/3 / 10/2 | 0.02 |
| Max ANCA titrea | 40 (30–100) / 200 (80–560) | 0.16 |
| Max PR3-ANCA titrea | 0 (0.0–0.0) / 200 (40–320) | <0.001 |
| Max white blood cells [103cells/μl] | 15.5 ± 9.7 / 14.6 ± 5.3 | 0.79 |
| Max blood eosinophilia [cells/μl] | 6964 ± 8552 / 227 ± 72 | 0.02 |
| Max CRP [mg/l] | 37.0 ± 11.6 / 86.7 ± 55.1 | 0.009 |
| Min creatinine clearance [ml/min] | 84.7 ± 18.3 / 87.2 ± 40.6 | 0.86 |
| Ever treated: C | 9/10 | 0.48 |
| Ever treated: G | 11/10 | >0.99 |
Az azathioprine, C cyclophosphamide, Cy cyclosporine, G glucocorticoids, M methotrexate, Max maximal, Min minimal
amedian with interquartile range for patients with positive ANCA
Cumulative organ involvement in subjects with CSS and WG with regard to presence of prior clinical cardiac manifestation
| Organ involvement | CSS | WG | All | |||
|---|---|---|---|---|---|---|
| Heart (+) / Heart (−) |
| Heart (+) / Heart (−) |
| CCS / WG |
| |
| Upper respiratory tract | 3 / 8 | >0.99 | 2 / 8 | >0.99 | 11 / 10 | >0.99 |
| Bronchial asthma | 3 / 8 | >0.99 | 0 / 0 | >0.99 | 11 / 0 | <0.001 |
| Lung | 3 / 7 | >0.99 | 1 / 8 | 0.20 | 10 / 9 | >0.99 |
| Kidney | 0 / 4 | 0.24 | 1 / 6 | >0.99 | 4 / 7 | 0.20 |
| Skin | 1 / 6 | 0.49 | 0 / 4 | 0.47 | 7 / 4 | 0.39 |
| Heart | 3 / 0 | 0.006 | 2 / 0 | 0.02 | 3 / 2 | >0.99 |
| Eye | 0 / 0 | >0.99 | 0 / 2 | >0.99 | 0 / 2 | 0.21 |
| Gastrointestinal tract | 0 / 3 | 0.49 | 0 / 2 | >0.99 | 3 / 2 | >0.99 |
| Peripheral nervous system | 1 / 5 | 0.54 | 1 / 2 | >0.99 | 6 / 3 | 0.39 |
| Central nervous system | 0 / 1 | >0.99 | 1 / 0 | 0.20 | 1 / 1 | >0.99 |
| Rheumatic complications | 2 / 4 | >0.99 | 0 / 3 | >0.99 | 6 / 3 | 0.39 |
| Constitutional symptoms | 3 / 7 | >0.99 | 2 / 5 | >0.99 | 10 / 7 | 0.31 |
| Cumulative DEI | 9.7 ± 3.1 / 10.4 ± 1.6 | 0.62 | 9.0 ± 2.8 / 9.4 ± 2.4 | 0.89 | 10.2 ± 1.9 / 9.3 ± 3.2 | 0.45 |
CMR findings in subjects with CSS, WG and controls
| CMR parameters | CSS (n = 11) / WG (n = 10) |
| All (n = 21) / Controls (n = 21) |
|
|---|---|---|---|---|
| LVEF [%] | 68.0 ± 6.1 / 66.0 ± 5.0 | 0.89 | 66.2 ± 5.8 / 63.4 ± 3.4 | 0.13 |
| LVEDV index [ml/m2] | 66.1 ± 4.0 / 66.1 ± 8.5 | 0.99 | 66.1 ± 6.6 / 69.9 ± 8.2 | 0.15 |
| LV mass index [g/m2] | 56.9 ± 7.8 / 65.5 ± 8.6 | 0.02 | 61.0 ± 8.9 / 49.7 ± 7.8 | <0.001 |
| RVEF [%] | 63.7 ± 3.7 / 58.9 ± 6.3 | 0.05 | 61.4 ± 5.7 / 60.3 ± 7.1 | 0.60 |
| RVEDV index [ml/m2] | 68.0 ± 6.9 / 69.6 ± 9.0 | 0.65 | 68.8 ± 7.8 / 71.9 ± 8.3 | 0.28 |
| RV mass index [g/m2] | 17.8 ± 3.2 / 16.7 ± 1.9 | 0.36 | 17.3 ± 2.5 / 17.6 ± 2.2 | 0.68 |
| Myocardial SI-T2 ratio at mid LV level | 1.2 ± 0.2 / 1.3 ± 0.2 | 0.33 | 1.3 ± 0.2 / 1.2 ± 0.3 | 0.37 |
| Myocardial EGE ratio at mid LV level | 2.2 ± 0.8 / 2.3 ± 0.3 | 0.71 | 2.2 ± 0.6 / 2.2 ± 0.9 | 0.88 |
| Pericardial effusion | 2 / 2 | >0.99 | 4 / 0 | 0.11 |
| Localized pericardial thickening | 2 / 4 | 0.36 | 6 / 0 | 0.02 |
| Decreased εps ≥2 LV segments | 9 / 8 | >0.99 | 17 / 0 | <0.001 |
| Decreased εps: total (mean) LV segment number | 66 (6.0 ± 3.4) / 70 (7.0 ± 3.9) | >0.99 (0.53) | 136 (6.5 ± 3.6) / 4 (0.2 ± 0.4) | <0.001 (< 0.001) |
|
| ||||
| Longitudinally: total (mean) LV segment number | 49 (4.5 ± 2.8) / 32 (3.2 ± 2.3) | 0.12 (0.28) | 81 (3.9 ± 2.6) / 2 (0.1 ± 0.3) | <0.001 (<0.001) |
| Circumferentially: total (mean) LV segment number | 12 (1.6 ± 1.7) / 24 (2.4 ± 1.6) | 0.06 (0.32) | 36 (2.0 ± 1.7) / 2 (0.1 ± 0.3) | <0.001 (<0.001) |
| Radially: total (mean) LV segment number | 18 (1.1 ± 1.1) / 29 (2.9 ± 1.7) | 0.05 (0.01) | 47 (2.0 ± 1.7) / 2 (0.1 ± 0.3) | <0.001 (<0.001) |
| LVLGE: present (segment number) | 9 (2.2 ± 1.7) / 8 (2.5 ± 2.3) | 0.64 (0.72) | 17 (2.3 ± 2.0) / 0 (0.0 ± 0.0) | <0.001 (<0.001) |
| LVLGE: subendocardial/midwall/subepicardial | 3/5/4 / 3/5/4 | >0.99 | 6/10/8 / 0/0/0 | <0.001 |
| RVLGE: present (segment number) | 4 (0.8 ± 1.0) / 3 (0.6 ± 1.1) | >0.99 (0.80) | 7 (0.7 ± 1.2) / 0 (0.0 ± 0.0) | 0.009 (0.01) |
Fig. 1Late gadolinium enhancement (LGE) lesions (arrows) in (a) two-chamber apical long-axis view in 59 years old male with granulomatosis with polyangiitis (Wegener’s) (WG) and (b) mid ventricular short axis view in 53 years old male with Churg–Straus syndrome (CSS)
Fig. 2Intra and interobserver reproducibility of segmental longitudinal (a), circumferential (b) and radial (c) peak-systolic strain (εps) measurements. SD standard deviation
The mean segmental longitudinal, circumferential and radial peak-systolic strain (εps) in subjects with Churg–Strauss syndrome (CSS), granulomatosis with polyangiitis (Wegener’s) (WG), controls as well as with regard to the spatial distribution of late gadolinium enhancement (LGE) lesions
| Segmental εps | CSS (n = 11) | WG (n = 10) | Subendocardial LGE (n = 6) | Midwall | Subepicardial LGE (n = 8) | Controls (n = 21) |
|---|---|---|---|---|---|---|
| Longitudinal [%] | −20.2 ± 10.0* | −20.4 ± 9.6* | −11.8 ± 5.6* | −13.2 ± 5.5* | −19.7 ± 2.9 | −22.7 ± 5.1 |
| Circumferential [%] | −24.0 ± 7.0 | −23.5 ± 7.8 | −22.6 ± 3.1 | −16.6 ± 4.2* | −21.9 ± 2.8 | −23.6 ± 5.6 |
| Radial [%] | 30.5 ± 13.3 | 29.5 ± 17.3 | 26.8 ± 8.4 | 18.8 ± 8.1* | 13.7 ± 8.7* | 34.2 ± 15.7 |
* p < 0.01 when compared to controls
No difference in mean segmental longitudinal εps between CSS and WG were found for longitudinal (p = 0.91), circumferential (p = 0.57) and radial (p = 0.65) measurements
Fig. 3Peak-systolic strain (εps) with regard to the spatial distribution of late gadolinium enhancement (LGE) lesions (arrows) in subjects with Churg–Strauss syndrome (CSS) (a, c) and granulomatosis with polyangiitis (Wegener’s) (WG) (b). εps was decreased longitudinally for subendocardial LGE (a), radially for subepicardial LGE (b), and circumferentially, longitudinally and radially for midwall LGE (c) lesions